Researchers at the University of California San Diego and the Massachusetts Institute of Technology (MIT) have come up with a strategy for using synthetic biology in therapeutics. The approach enables continual production and release of drugs at disease sites in mice while simultaneously limiting the size, over time, of the populations of bacteria engineered to produce the drugs. The findings are published in the July 20 online issue of Nature.
UC San Diego researchers led by Jeff Hasty, a professor of bioengineering and biology, engineered a clinically relevant bacterium to produce cancer drugs and then self-destruct and release the drugs at the site of tumors. The team then transferred the bacterial therapy to their MIT collaborators for testing in an animal model of colorectal metastasis. The design of the therapy represents a culmination of four previous Nature papers from the UC San Diego group that describe the systematic development of engineered genetic clocks and synchronization. Over the years, the researchers have employed a broad approach that spans the scales of synthetic biology,
The new study offers a therapeutic approach that minimizes damage to surrounding cells.
“In synthetic biology, one goal of therapeutics is to target disease sites and minimize damage,” said UC San Diego bioengineering and biology professor Jeff Hasty. He wondered if a genetic “kill” circuit could be engineered to control a population of bacteria in vivo, thus minimizing their growth. “We also wanted to deliver a significant therapeutic payload to the disease site.”
In order to achieve this, he and his team synchronized the bacteria to release bursts of known cancer drugs when a bacterial colony self-destructs within the tumor environment. The use of bacteria to deliver cancer drugs in vivo is enticing because conventional chemotherapy doesn’t always reach the inner regions of a tumor, but bacteria can colonize there. Importantly, the researchers observed that the combination of chemotherapy and the gene products produced by the bacterial circuit consistently reduced tumor size.
“The new work by Jeff Hasty and team is a brilliant demonstration of how theory in synthetic biology can lead to clinically meaningful advances,” said Jim Collins, a professor at MIT who is known as a founder of the field of synthetic biology. “Over a decade ago during the early days of the field, Jeff developed a theoretical framework for synchronizing cellular processes across a community of cells. Now his team has shown experimentally how one can harness such effects to create a novel, clinically viable therapeutic approach.”
Limiting the bacterial population
In order to observe the bacterial population dynamics, the researchers designed custom microfluidic devices for careful testing before investigations in animal disease models. Consistent with the engineering design, they observed cycling of the bacterial population that successfully limits overall growth while simultaneously enabling production and release of encoded cargo. When the bacteria were equipped with a gene that drives production of a therapeutic, the synchronized lysis of the bacterial colony was shown to kill human cancer cells. It is the first engineered gene circuit in synthetic biology to achieve these objectives.
The Latest on: Synthetic biology
via Google News
The Latest on: Synthetic biology
- Self-lighting Christmas trees with synthetic DNA on December 24, 2018 at 7:25 am
Engineers and biologists the university’s Interactive Synthetic Biology Centre used virtual reality to demonstrate the theory, which involves synthesising a DNA sequence by making a copy of the gene i... […]
- DNA Synthesis Market size in terms of volume and value on December 21, 2018 at 1:09 pm
DNA synthesis market further includes the oligonucleotide synthesis and gene synthesis which has various end users such as agricultural science, food science, antibody discovery, immunology, cancer re... […]
- $1B start-up backed by Bill Gates prints new DNA — and everyone from the DOD to Bayer is on board on December 21, 2018 at 12:00 pm
Thanks to its ground-breaking synthetic biology projects, the company is reportedly valued at more than $1 billion after raising over $429 million in total funding from its investors, who include Casc... […]
- Synthetic biology goes to SPAAAAAAACE! on December 20, 2018 at 11:20 am
If humanity is going to push the boundaries of space exploration, we're going to need plants to come along for the ride. Not just spinach or potatoes, though--plants can do so much more than just feed ... […]
- Expanded Centre for Synthetic Biology launches at Imperial on December 20, 2018 at 3:32 am
The Centre brings together researchers using synthetic biology to solve challenges such as in healthcare, biomaterials and sustainable energy. Synthetic biology is the application of engineering princ... […]
- Lambert students earns gold for biology presentation on December 18, 2018 at 4:37 pm
The team competed with more than 340 teams from around the world at the annual Giant Jamboree, an international forum hosted by iGEM, an organization that focuses on synthetic biology. iGEM stands for ... […]
- Military eyes ‘synthetic biology’ to track enemy movements on December 18, 2018 at 12:16 pm
In an effort that sounds like it came straight from a science-fiction movie, the Department of Defense has announced it’s exploring the use of genetically altered marine life forms to track ... […]
- Synthetic biology start-up Colorifix raises $3m to scale its textile dyeing solution on December 18, 2018 at 4:17 am
The funds will support the expansion of the company’s Norwich-based facility and the team build-out as Colorifix launches a number of pilots with several leading players in the international fashion i... […]
- Synthetic Biology Market is Expected to show Wide Growth Globally by 2024 | Hexa Research on December 18, 2018 at 3:13 am
"Fact-based market research, penetrating industry insights and validated forecasts to help you make better decisions for a stronger future" Research Report on Synthetic Biology Market Analysis, By Pro... […]
- SoftBank returns to back synthetic biology firm Zymergen in a $400M series C round on December 14, 2018 at 12:29 pm
Zymergen has raised over $400 million in a series C funding round, which it says will help double the capacity of its synthetic biology contract manufacturing platform. It will also use the money to b... […]
via Bing News